Psychobiotics are living organisms that, on sufficient ingestion, produce a health benefit in patients with psychiatric, or neurological, illnesses. Research to understand the impact of psychobiotics on the gut–brain axis, enteric nervous system, and oral-microbiome, is currently under way.
Psychobiotics is a relatively recent term. While it’s been known for over a century that bacteria can have positive effects on physical health, only studies in the last 10-15 years have shown that there is a gut-brain connection.
A previous systematic review from 2016 examined the preclinical and small human trials that have been conducted with certain commercially available strains of probiotic bacteria and found that among those tested, Bifidobacterium and Lactobacillus genera (B. longum, B. breve, B. infantis, L. helveticus, L. rhamnosus, L. plantarum, and L. casei), had the most potential to be useful for certain central nervous system disorders.
Cautious Psychobiotics Optimism
The science of psychobiotics, reviewed in a recent paper in Trends in Neurosciences, explores emerging strategies for planting brain-altering bacteria in the gut to provide mental benefits and the challenges ahead in understanding how such products could work for humans.
Now that we know that gut bacteria can speak to the brain, in ways that affect our mood, our appetite, and even our circadian rhythms, the next challenge for scientists is to control this communication.
While it’s been known for over a century that bacteria can have positive effects on physical health, only studies in the last 10-15 years have shown that there is a gut-brain connection. In mice, enhanced immune function, better reactions to stress, and even learning and memory advantages have been attributed to adding the right strain of bacteria.
Human studies are more difficult to interpret because mood changes in response to probiotics are self-reported, but physiological changes, such as reduced cortical levels and inflammation, have been observed.
Sarkar et al./Trends in Neurosciences 2016
Lead author Philip Burnet, an associate professor of psychiatry at the University of Oxford, says:
“Those studies give us confidence that gut bacteria are playing a causal role in very important biological processes, which we can then hope to exploit with psychobiotics. We’re now on the search for mechanisms, mainly in animal models.
The human studies are provocative and exciting, but ultimately, most have small sample sizes, so their replicability is difficult to estimate at present. As they say, we’re ‘cautiously optimistic.'”
Brain-derived Neurotrophic Factor
Researchers seem to agree that the key players responsible for the bacteria-gut-brain axis, the nervous system of the intestines, the immune system, the vagus nerve, and possibly gut hormones and neurotransmitters (e.g., serotonin and dopamine), are involved.
What varies is the excitement about the use of psychobiotics as methods of treatment for psychological disorders and enhancing cognition.
For example, in mice we know that psychobiotics often increase brain-derived neurotrophic factor (BDNF), which is closely linked to learning and memory. At present, we have no way of knowing whether psychobiotics affect BDNF in humans, and a systematic review recently found no overall benefit of probiotic ingestion in humans.
However, probiotics are only part of the story.
“Prebiotics (nutrition for gut bacteria) are another channel to alter gut bacteria,” Burnet says. “We call for an even further widening of the definition of ‘psychobiotics’ to include drugs such as antidepressants and antipsychotics, and activities such as exercise and eating, because of their effects on gut bacteria.”
For now, consumers of probiotics and prebiotics should be skeptical about products currently advertised to have psychobiotic effects.
Such supplements have a lot of promise as “add-on” therapies for antidepressants or antipsychotics, but many more questions need to be answered about what strains of bacteria offer specific benefits, how they work, whether they offset other benefits, and how they will be regulated.
“Psychobiotics are a long way from their true translational potential. It’s a little boring to say that we need more studies, but that is always the case in any academic discipline,” Burnet says. “The technology and resources already exist for such investigations, so though we are enthusiastic, the enthusiasm needs to be tempered and channeled toward answering the core mechanistic questions.”